The cancer drug Gleevec is extremely specific, binding and inhibiting only the cancer-causing tyrosine protein kinase Blc-Abl, while not targeting homologous protein kinases found in normal, healthy cells. Researchers at the ALS have uncovered exactly why that is the case, pointing to novel methods of drug discovery. Read more »
ALSNews Vol. 365
JUNE 30, 2015
Tracking the Elusive QOOH Radical
For the first time, researchers directly observed QOOH molecules, a class of highly reactive molecules at the center of the web of ignition chemistry reactions. The data generated will improve the fidelity of combustion models used to create cleaner and more efficient cars and trucks. Read more »
ALS Postdoc Recognized for Outstanding Thesis
Søren Ulstrup, an ALS postdoc who received his Ph.D. from Aarhus University in Denmark last year, was selected by the Aarhus University Research Foundation as one of five promising young scientists to receive its prize for outstanding doctoral thesis. Watch a video of Søren describing his thesis, “A Direct Study of the Electronic Structure of Graphene.” Read more »